Variances--an exception or departure from approved protocol--occur and this webinar will help you prepare for them.

A panel of experts help attendees understand the key elements of FDA's New Dietary Ingedient (NDI) draft guidance and how it will impact businesses in the supplement industry.

As much as 30% of the national sales of dietary supplements may be to California consumers - but companies that market in that state may encounter high penalties for non-compliance with a California law known as Proposition 65. The focus of this law for the supplement class has been on the warnings required for products that may inadvertently contain small amounts of heavy metals, such as arsenic, cadmium, and mercury, and especially lead.

This Guidance for Addressing FDA Inspections of Dietary Supplement Facilities has been prepared to assist AHPA members in understanding their rights and obligations when the U.S. Food and Drug Administration conducts an inspection of a facility in which dietary supplements or ingredients are manufactured, processed, packed or held. It provides descriptions and analyses of the current federal laws that are relevant to inspection of dietary supplement facilities and suggestions of how to prepare for and conduct inspections in a manner that fully complies with these laws.

This webinar covers the extent of FDA's authority during an inspection, so you know your rights.

Learn how to create, manage and control documents for good GMP practices, inspectors, auditors and safety.

Under the cGMP rule, it is the responsibility of the manufacturer to identify contaminants likely or certain to be present in or on components received and to establish limits to prevent adulteration of these components.

An expert panel provide practical. first-hand knowledge and answer questions about sustainability and how to walk the walk in a “greenwashed” world.

The new Good Manufacturing Practice regulations for dietary supplements require that manufacturers with shelf life statements on their labels have appropriate scientific substantiation

This debriefing provides expertise to answer specific questions and dispel any confusion that arose from the FDA overview of cGMP implementation guidance.